AlphaCrest Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

AlphaCrest Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-24,383	Closed	-$1.01M	–	891
2022 Q3	$1.01M	Buy	+24,383	New	+$1.25M	0.06%	608
2022 Q2	–	Sell	-7,015	Closed	-$509K	–	1350
2022 Q1	$509K	Buy	7,015 +3,725	+113%	+$259K	0.03%	888
2021 Q4	$277K	Sell	3,290 -3,158	-49%	-$257K	0.01%	1273
2021 Q3	$582K	Sell	6,448 -6,353	-50%	-$574K	0.03%	851
2021 Q2	$1.22M	Buy	+12,801	New	+$1.33M	0.05%	566
2020 Q4	–	Sell	-6,542	Closed	-$538K	–	1246
2020 Q3	$538K	Buy	6,542 +3,800	+139%	+$315K	0.06%	544
2020 Q2	$214K	Sell	2,742 -4,574	-63%	-$303K	0.04%	814
2020 Q1	$325K	Buy	+7,316	New	+$380K	0.04%	769
2019 Q3	–	Sell	-4,311	Closed	-$274K	–	1323
2019 Q2	$274K	Buy	+4,311	New	+$274K	0.02%	890

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

AlphaCrest Capital Management's RARE Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2022, closing a stake of 24,383 shares — an estimated $1.01M sold.

AlphaCrest Capital Management first reported a position in RARE in Q2 2019 and held it in 9 quarters. The position peaked at $1.22M in Q2 2021. 228 funds tracked by Wall St. Rank hold RARE as of Q4 2022.

AlphaCrest Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 24,383 Ultragenyx Pharmaceutical shares in Q4 2022, an estimated $1.01M.
AlphaCrest Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2019 and held it in 9 quarters.
AlphaCrest Capital Management's Ultragenyx Pharmaceutical position peaked at $1.22M in Q2 2021.
228 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.